Doctors Note Logo

Published on: 1/14/2026

What is farxiga 10 mg used for?

Farxiga 10 mg (dapagliflozin) is an FDA-approved SGLT2 inhibitor prescribed to:

  • Control blood sugar in adults with type 2 diabetes
  • Reduce cardiovascular death and hospitalization in patients with heart failure (including reduced ejection fraction)
  • Slow chronic kidney disease (CKD) progression and lower kidney or cardiovascular event risk, even in people without diabetes

Key considerations before starting Farxiga 10 mg include contraindications (such as severe kidney impairment or dialysis), potential side effects like genital yeast infections, urinary tract infections, dehydration, and rare but serious diabetic ketoacidosis. Drug interactions and routine kidney function monitoring are also important.

Because Farxiga treats overlapping conditions—diabetes, heart failure, and kidney disease—understanding your specific symptoms is essential to knowing whether this medication fits your situation and what to discuss with your clinician. Guessing can delay care or lead to missed warning signs. Take a free, private, instant symptom check now to clarify what's going on and confidently plan your next steps.

Reviewed for medical accuracy: 07/09/2026

answer background

Explanation

What Is Farxiga 10 mg Used For?

Farxiga (dapagliflozin) 10 mg is a prescription medication belonging to a class of drugs called sodium-glucose cotransporter-2 (SGLT2) inhibitors. It works by helping the kidneys remove excess glucose (sugar) from the bloodstream through urine. Beyond its role in blood sugar control, Farxiga has demonstrated significant benefits in heart and kidney health.

How Farxiga Works

  • Blocks SGLT2 proteins in the kidney, reducing glucose reabsorption
  • Promotes urinary glucose excretion, lowering blood sugar levels
  • Reduces fluid overload by increasing urine output, aiding heart function

FDA-Approved Uses of Farxiga 10 mg

  1. Type 2 Diabetes Mellitus
    • As an adjunct to diet and exercise to improve glycemic control.
    • Often prescribed when first-line therapies (e.g., metformin) are inadequate.

  2. Heart Failure with Reduced Ejection Fraction (HFrEF)
    • Based on the DAPA-HF trial (McMurray et al., Lancet 2019), Farxiga reduced the risk of cardiovascular death and hospitalization for heart failure in patients with an ejection fraction ≤ 40%.
    • Benefits seen regardless of whether a patient has diabetes.

  3. Chronic Kidney Disease (CKD)
    • The DAPA-CKD trial (Heerspink et al., N Engl J Med 2020) showed Farxiga slowed kidney function decline and lowered the risk of kidney failure or death in patients with CKD, with or without type 2 diabetes.

Key Clinical Evidence

  • DAPA-HF (McMurray JJV et al., 2019):
    • Population: Patients with HFrEF, mean age ~66 years
    • Outcome: 26% relative risk reduction in CV death or heart failure hospitalization

  • DAPA-CKD (Heerspink HJL et al., 2020):
    • Population: CKD patients, eGFR 25-75 mL/min/1.73 m², elevated albuminuria
    • Outcome: 39% relative risk reduction in composite of sustained decline in kidney function, end-stage kidney disease, or renal/CV death

Potential Benefits

  • Improved blood sugar control in type 2 diabetes
  • Lower risk of heart failure hospitalization and cardiovascular death
  • Slower progression of chronic kidney disease
  • Modest weight loss through glucose excretion and mild diuretic effect
  • Potential blood pressure reduction (due to mild diuresis)

Common Side Effects

  • Genital yeast infections (men and women)
  • Urinary tract infections
  • Increased urination and thirst
  • Potential dehydration, dizziness, or low blood pressure

Less Common but Serious Risks

  • Ketoacidosis (a buildup of acids called ketones in the blood)
  • Acute kidney injury (rare)
  • Serious urinary tract infections
  • Fournier's gangrene (rare, serious genital infection)

Always report signs of serious reactions—such as rapid breathing, confusion, severe abdominal pain, or signs of infection—to your healthcare provider immediately.

Precautions and Considerations

  • Not approved for type 1 diabetes or diabetic ketoacidosis treatment
  • Use caution if you have low blood pressure, dehydration, or kidney impairment
  • Discuss any history of genital infections or urinary tract infections with your doctor
  • May interact with diuretics, blood pressure medications, or other glucose-lowering drugs

Monitoring and Follow-Up

  • Regular kidney function tests (eGFR, serum creatinine)
  • Blood glucose and HbA1c monitoring in diabetes
  • Electrolytes and blood pressure checks
  • Assess for symptoms of heart failure (shortness of breath, swelling)

When to Seek Medical Advice

If you experience:

  • Sudden weight gain, leg swelling, or worsening shortness of breath
  • Signs of ketoacidosis (nausea, vomiting, abdominal pain, confusion)
  • High fever or severe urinary/genital pain
  • Dizziness, fainting, or signs of low blood pressure

…you should speak to a healthcare professional without delay. If you're experiencing concerning symptoms and aren't sure whether they require immediate attention, you can use a free AI symptom checker to help assess your situation and guide your next steps.

Talking to Your Doctor

Farxiga can offer benefits for diabetes, heart failure, and kidney disease, but it's not right for everyone. Always discuss:

  • Your full medical history
  • Current medications and supplements
  • Any allergies or past drug reactions
  • Pregnancy or breastfeeding plans

Never stop or change your dose of Farxiga without your doctor's approval.


Remember: This information is for educational purposes and does not replace professional medical advice. If you're experiencing life-threatening symptoms or serious concerns, please call your doctor or emergency services immediately.

(References)

  • McMurray JJV, et al. (2019). Dapagliflozin in Patients with Heart Failure and Reduced Ejection… Lancet, 31504403.

  • Heerspink HJL, et al. (2020). Dapagliflozin in Patients with Chronic Kidney Disease… N Engl J Med, 33315140.

  • Ziol M, et al. (2005). Noninvasive assessment of liver fibrosis by transient elastography:… Gastroenterology, 15788340.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.